Linked Life Data

18635842

Source:http://linkedlifedata.com/resource/pubmed/id/18635842

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2008-9-30
pubmed:abstractText
The neutral results of the SAINT II trial have again highlighted difficulties translating neuroprotective efficacy from bench to bedside. Animal studies are susceptible to study quality biases, which may lead to overstatement of efficacy. We report the impact of study quality on published estimates of the efficacy of NXY-059 in animal models of stroke.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1524-4628
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2824-9
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality.
pubmed:affiliation
Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, Scotland, UK. malcolm.macleod@ed.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Meta-Analysis